Samantha Marsee
Primary Care · Bel Air, MDNPI 1972240588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$547
- Novo Nordisk$369
- AbbVie$315
- Lilly USA, LLC$232
- Exact Sciences$215
- GSK$177
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $547 |
| Novo Nordisk | 15 | $369 |
| AbbVie | 14 | $315 |
| Lilly USA, LLC | 12 | $232 |
| Exact Sciences | 10 | $215 |
| GSK | 8 | $177 |
| Esperion Therapeutics, Inc. | 9 | $158 |
| Pfizer | 6 | $123 |
| Amgen | 5 | $108 |
| Merck | 5 | $94 |
| Astellas Pharma US Inc | 4 | $90 |
| Edwards Lifesciences | 1 | $81 |
| Novartis | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Dexcom, Inc. | 3 | $57 |
| Johnson & Johnson | 2 | $42 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Mylan Specialty L.p. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,911 in reported general payments places this provider in the 90th percentile of 191 primary care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 24 | $32,111 |
| RybelsusSemaglutide | 12 | $24,482 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $20,343 |
| FarxigaDapagliflozin Propanediol | 11 | $11,404 |
| Victoza 3-PakLiraglutide | 11 | $10,174 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $3,367 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,069 |
| Atorvastatin Calcium | 168 | $2,600 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,655 |
| Ezetimibe | 27 | $1,631 |
| Metoprolol Succinate | 83 | $1,302 |
| Amlodipine Besylate | 115 | $1,195 |
| Lisinopril | 139 | $975 |
| Levothyroxine Sodium | 76 | $696 |
| Nifedipine ErNifedipine | 11 | $643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $32,11124 claims |
| Novo NordiskRybelsus | $369 | $24,48212 claims |
| GSKTrelegy Ellipta | $177 | $20,34319 claims |
| AstraZenecaFarxiga, Symbicort | $547 | $14,47322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 primary care providers in Maryland.
Other primary care in Bel Air
- Laura Ferguson-WeigmanBel Air$5K
- Mary WeberBel Air$3K
- Taylor Melton-FarleyBel Air$3K
- Vicki HyattBel Air$3K
- Tara McDonaldBel Air$2K
- Donna BakerBel Air$2K
- Kimberly MorelandBel Air$2K
- Agatha HughesBel Air$2K
- Tyler CoakleyBel Air$798
- Ashley SalamoneBaltimore$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.